CD44v6

Product List

Creative Biolabs provides a wide selection of CD44V6 molecular-related items, such as CAR vector items, CAR cell items, CAR viral particles, CAR animal cells, etc. These offerings aim to support the progress of CD44V6-targeted CAR-T therapy. Please refer to the list below to find the product that you need.

Background

As a glycoprotein found on the surface of cells, CD44 plays a role in the growth, differentiation, and spread of tumors. CD44v6 is a specific variant of CD44 that is mainly expressed at high levels in solid cancers. It has been involved in the development of tumors, the invasion of tumor cells, and the spread of cancer. CD44v6 also includes exon 11 and is highly expressed in various types of malignancies, including squamous cell carcinomas in the head, neck, lung, skin, cervix, and esophagus, as well as breast, gastrointestinal, hepatocellular, and colorectal cancers, and certain subtypes of acute myeloid leukemias (AML). The effectiveness of using a CD44v6 chimeric antigen receptor (CAR) has been investigated in clinical trials for the treatment of AML, multiple myeloma, and solid cancers.

Fig.1 Schematic structure of the CD44v6-LNGFR CAR.¹

Anti-CD44V6 CAR-T Services

Anti-CD44V6 CAR-T In Vitro Assay Services

CD44V6 CAR-T Expression Test

Creative Biolabs offers a complete series of protein products to detect the expression of anti-CD44v6 CART cells. These protein and cell products have been widely used for the expression test of anti-CD44v6 CAR-T cells.

• Unconjugated CD44v6
• Biotinylated CD44v6
• Fluorescent-labeled CD44v6
• Custom cells with CD44v6 overexpression

Fig.2 Biochemical analysis of the CD44v6 CAR expression.¹

CD44V6 CAR-T Cytokine Release Test

The production of intracellular cytokines (such as TNF-α and IFN-γ) can be assessed using flow cytometry on CAR T cells that have been cultured with various types of target cells.

Fig.3 Analysis of intracellular cytokine production of CD44v6 CAR T cells by flow cytometry.¹

CD44V6 CAR-T In Vitro Cytotoxicity Assay

CD44v6 CAR-T exhibits only mild damage to human umbilical vein endothelial cells (HUVECs) and slight non-tumor cytotoxicity towards T lymphocytes. Creative Biolabs provides exclusive cytotoxicity testing services specifically designed for CD44v6 CAR-T cells. CD44v6-positive tumor cell lines can be used for this purpose.

Fig.4 Cytotoxic activity of the differentiated CD44v6 CAR T cells. ¹

CD44V6 CAR-T Cell Proliferation Test

We assure our customers that Creative Biolabs provides top-notch service for customized CAR-T cell proliferation assays.

Fig.5 Impact of spacer region of CD44v6 CART on T cells proliferation and activation.¹

Anti-CD44V6 CAR-T In Vivo Assay Services

CD44V6 CAR-T Cell Therapy Animal Models

Creative Biolabs has developed a diverse selection of efficient models for in vivo evaluation, including immune-oncology animal models, syngeneic models, humanized mice models, patient-derived xenografted (PDX) models, patient-derived organoid models, and cell line-derived xenografted (CDX) models for CD44v6 CAR-T therapy.

Fig.6 In vivo antitumor activity of CD44v6 CART analyzed in THP-1 high-burden disease model.¹

Efficacy Test of CD44V6 CAR-T

We have a variety of testing methods at our disposal, such as in vivo imaging, flow cytometry, histologic and pathologic analysis, and clinical observation, enabling us to assess the therapeutic effectiveness of CD44v6 CAR-T cell therapy.

Fig.7 Analysis of potent anti-tumor efficacy of CD44v6 CAR-T cells in vivo.²

Toxicity Evaluation of CD44V6 CAR-T

Creative Biolabs offers CAR-T cell toxicity evaluation service, leveraging our profound expertise in preclinical in vivo research, project management, and our ability to employ suitable models, design comprehensive research protocols, and conduct reliable high-quality in vivo studies.

Please feel free to get in touch with us for more information on CD44V6 CAR-related services and products.

References

1. Stornaiuolo, Anna, et al. "Characterization and functional analysis of CD44v6. CAR T cells endowed with a new low-affinity nerve growth factor receptor-based spacer." Human Gene Therapy 32.13-14 (2021): 744-760.
2. Tang, Ling, et al. "CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations." Clinical and Translational Medicine 12.9 (2022): e1043.